Emerald Mutual Fund Advisers Trust’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,244	Closed	-$201K	–	252
2022 Q3	$201K	Sell	3,244 -1,629	-33%	-$114K	0.01%	184
2022 Q2	$389K	Buy	4,873 +819	+20%	+$77.6K	0.02%	157
2022 Q1	$427K	Buy	4,054 +367	+10%	+$35.8K	0.02%	161
2021 Q4	$397K	Sell	3,687 -280	-7%	-$30.5K	0.01%	178
2021 Q3	$435K	Hold	3,967	–	–	0.02%	186
2021 Q2	$371K	Hold	3,967	–	–	0.01%	188
2021 Q1	$365K	Sell	3,967 -1,950	-33%	-$165K	0.01%	191
2020 Q4	$433K	Sell	5,917 -544,228	-99%	-$40.5M	0.02%	196
2020 Q3	$42.7M	Sell	550,145 -191,692	-26%	-$13.2M	1.89%	7
2020 Q2	$41.2M	Sell	741,837 -371,444	-33%	-$15.9M	1.95%	3
2020 Q1	$33M	Sell	1,113,281 -72,235	-6%	-$2.44M	2.07%	5
2019 Q4	$42.9M	Buy	1,185,516 +1,737	+0.1%	+$53.3K	1.75%	5
2019 Q3	$32.2M	Sell	1,183,779 -5,077	-0.4%	-$131K	1.43%	14
2019 Q2	$28.6M	Buy	1,188,856 +900	+0.1%	+$22.8K	1.14%	25
2019 Q1	$31.4M	Buy	1,187,956 +301,456	+34%	+$7.14M	1.26%	16
2018 Q4	$17.3M	Buy	+886,500	New	+$17.4M	0.81%	43
2016 Q3	–	Sell	-31,117	Closed	-$512K	–	299
2016 Q2	$512K	Buy	31,117 +12,176	+64%	+$197K	0.03%	209
2016 Q1	$314K	Buy	+18,941	New	+$331K	0.02%	229
2015 Q2	–	Sell	-294,868	Closed	-$8.72M	–	274
2015 Q1	$8.72M	Sell	294,868 -306,851	-51%	-$5.62M	0.71%	56
2014 Q4	$7.76M	Buy	601,719 +143,763	+31%	+$1.8M	0.67%	57
2014 Q3	$5.62M	Sell	457,956 -191,076	-29%	-$2.22M	0.54%	68
2014 Q2	$10.3M	Buy	649,032 +13,170	+2%	+$188K	0.94%	38
2014 Q1	$9.61M	Buy	+635,862	New	+$7.18M	0.92%	34

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's HZNP Position: Q4 2022 in Review

Emerald Mutual Fund Advisers Trust sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 3,244 shares — an estimated $201K sold.

Emerald Mutual Fund Advisers Trust first reported a position in HZNP in Q1 2014 and held it in 23 quarters. The position peaked at $42.9M in Q4 2019. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Emerald Mutual Fund Advisers Trust reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 3,244 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $201K.
Emerald Mutual Fund Advisers Trust first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 23 quarters.
Emerald Mutual Fund Advisers Trust's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $42.9M in Q4 2019.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2022, filed 3 Feb 2023.